Most-Upgraded StocksMost-UpgradedNASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Forecast, Price & News $114.00 -1.16 (-1.01%) (As of 12:09 PM ET) Add Compare Share Share Today's Range$113.62▼$115.4950-Day Range$98.79▼$117.1052-Week Range$89.04▼$129.29Volume136,045 shsAverage Volume756,027 shsMarket Capitalization$11.13 billionP/E Ratio65.90Dividend YieldN/APrice Target$128.52 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside12.2% Upside$128.52 Price TargetShort InterestHealthy2.07% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment1.00Based on 12 Articles This WeekInsider TradingSelling Shares$3.24 M Sold Last QuarterProj. Earnings Growth121.36%From $2.20 to $4.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.87 out of 5 starsMedical Sector57th out of 970 stocksBiological Products, Except Diagnostic Industry6th out of 158 stocks 3.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $128.52, Neurocrine Biosciences has a forecasted upside of 12.2% from its current price of $114.56.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.07% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 3.9 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Neurocrine Biosciences this week, compared to 6 articles on an average week.Search Interest7 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows7 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,238,890.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions93.54% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 121.36% in the coming year, from $2.20 to $4.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 66.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 66.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.05.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 1.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by AnalystsSeptember 26, 2023 | finance.yahoo.comThe $660 Million Opportunity That's Driving IBD Stock Of The Day Neurocrine Biosciences HigherSeptember 29, 2023 | PressReach (Ad)Uranium Prices Surge as Nuclear Energy Becomes KeyRenewed interest in uranium and rising prices have created a favorable environment for new projects.September 26, 2023 | finance.yahoo.comDow Jones Futures: As Market Correction Intensifies, What To Do; Meta AI Push In FocusSeptember 24, 2023 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Strong-Buy at StockNews.comSeptember 23, 2023 | americanbankingnews.comBarclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $134.00September 21, 2023 | markets.businessinsider.comPromising CAHtalyst Study Results and Anticipated Crinecerfont Uptake Drive Analyst’s ‘Buy’ Rating for NeurocrineSeptember 21, 2023 | finance.yahoo.comNeurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023September 29, 2023 | PressReach (Ad)Uranium Prices Surge as Nuclear Energy Becomes KeyRenewed interest in uranium and rising prices have created a favorable environment for new projects.September 14, 2023 | finance.yahoo.comDirector Gary Lyons Sells 5,000 Shares of Neurocrine Biosciences Inc (NBIX)September 14, 2023 | markets.businessinsider.comNeurocrine : FDA Accepts NDA For Ingrezza Oral Granules Sprinkle FormulationSeptember 14, 2023 | finance.yahoo.comNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle FormulationSeptember 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), HCA Healthcare (HCA)September 13, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Neurocrine (NBIX)September 12, 2023 | markets.businessinsider.comNeurocrine (NBIX) Receives a Buy from Goldman SachsSeptember 12, 2023 | msn.comWhat's Going On With Neurocrine Biosciences Stock Today?September 12, 2023 | finance.yahoo.comNeurocrine Biosciences Inc's Meteoric Rise: Unpacking the 22% Surge in Just 3 MonthsSeptember 12, 2023 | finance.yahoo.comCan Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?September 12, 2023 | markets.businessinsider.comNeurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of CrinecerfontSeptember 12, 2023 | finance.yahoo.comNeurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)September 11, 2023 | finance.yahoo.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy AdultsAugust 31, 2023 | finance.yahoo.comNeurocrine Biosciences to Present at Upcoming Investor Conferences in SeptemberAugust 29, 2023 | finance.yahoo.comNeurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) CapsulesAugust 28, 2023 | markets.businessinsider.comNeurocrine Reveals New Data On Ingrezza With Improvements In HD Chorea In Huntington's DiseaseAugust 28, 2023 | finance.yahoo.comNeurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's DiseaseAugust 25, 2023 | msn.comNeurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do ItAugust 22, 2023 | msn.comCantor Fitzgerald Reiterates Neurocrine Biosciences (NBIX) Overweight RecommendationSee More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Company Calendar Last Earnings8/01/2023Today9/29/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$128.52 High Stock Price Forecast$154.00 Low Stock Price Forecast$95.00 Forecasted Upside/Downside+11.6%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$1.73 Trailing P/E Ratio66.57 Forward P/E Ratio52.35 P/E Growth1.13Net Income$154.50 million Net Margins10.54% Pretax Margin13.99% Return on Equity10.39% Return on Assets7.44% Debt Debt-to-Equity RatioN/A Current Ratio2.57 Quick Ratio2.51 Sales & Book Value Annual Sales$1.49 billion Price / Sales7.55 Cash Flow$1.79 per share Price / Cash Flow64.35 Book Value$17.76 per share Price / Book6.48Miscellaneous Outstanding Shares97,650,000Free Float93,355,000Market Cap$11.25 billion OptionableOptionable Beta0.46 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 65)CEO & Director Comp: $1.9MMr. Matthew C. Abernethy (Age 43)Chief Financial Officer Comp: $1.04MMr. Darin M. Lippoldt Esq. (Age 57)Chief Legal Officer & Corp. Sec. Comp: $921.01kMr. Kyle W. Gano Ph.D. (Age 50)Chief Bus. Devel. and Strategy Officer Comp: $921.52kDr. Eiry Wyn Roberts M.D. (Age 59)Chief Medical Officer Comp: $1.04MDr. Jude Onyia Ph.D. (Age 59)Chief Scientific Officer Jane SorensenHead of Investor RelationsMs. Julie S. Cooke (Age 57)Chief HR Officer Mr. Eric S. Benevich (Age 58)Chief Commercial Officer Mr. David Warren Boyer (Age 44)Chief Corp. Affairs Officer More ExecutivesKey CompetitorsRepligenNASDAQ:RGENExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOBiogenNASDAQ:BIIBSeagenNASDAQ:SGENView All CompetitorsInsiders & InstitutionsGary A LyonsSold 5,000 sharesTotal: $575,100.00 ($115.02/share)Gary A LyonsSold 5,000 sharesTotal: $550,300.00 ($110.06/share)Julie CookeSold 824 sharesTotal: $91,406.32 ($110.93/share)David W BoyerSold 2,733 sharesTotal: $294,070.80 ($107.60/share)Ingrid DelaetSold 1,431 sharesTotal: $153,861.12 ($107.52/share)View All Insider TransactionsView All Institutional Transactions NBIX Stock - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price forecast for 2023? 21 brokerages have issued 12 month target prices for Neurocrine Biosciences' stock. Their NBIX share price forecasts range from $95.00 to $154.00. On average, they expect the company's stock price to reach $128.52 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2023? Neurocrine Biosciences' stock was trading at $119.44 on January 1st, 2023. Since then, NBIX shares have decreased by 3.6% and is now trading at $115.16. View the best growth stocks for 2023 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Tuesday, August, 1st. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.18. The business had revenue of $452.70 million for the quarter, compared to the consensus estimate of $448.29 million. Neurocrine Biosciences had a net margin of 10.54% and a trailing twelve-month return on equity of 10.39%. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and SPDR S&P Biotech ETF (XBI). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $115.16. How much money does Neurocrine Biosciences make? Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $11.25 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.73 on an earnings per share basis. How many employees does Neurocrine Biosciences have? The company employs 1,200 workers across the globe. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602. This page (NASDAQ:NBIX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.